Farxiga Tablet, Film Coated
Product Images NDC 0310-6210

13 FDA label images from Astrazeneca Pharmaceuticals Lp · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Farxiga (NDC 0310-6210). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Astrazeneca Pharmaceuticals Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Figure 4 (Figure 4)

Figure 4 (Figure 4)
A Kaplan-Meier curve showing the cumulative percentage of patients with an event over 60 months from randomization, comparing FARXIGA (dapagliflozin) versus placebo. The y-axis represents patients with the event (%) and the x-axis shows months. The graph includes numbers of patients at risk over time for each group.*
FDA Label Image

Figure 5 (Figure 5)

Figure 5 (Figure 5)
A line graph depicting the percentage of patients with an event over 60 months from randomization, comparing FARXIGA (dapagliflozin) versus placebo. The graph shows patients at risk numbers at several time points, illustrating a lower percentage of events in the FARXIGA group compared to placebo over time.*
FDA Label Image

Figure 6a (Figure 6a)

Figure 6a (Figure 6a)
A Kaplan-Meier plot comparing the percentage of patients with events over 24 months from randomization between FARXIGA and placebo. The graph shows hazard ratio, confidence interval, and p-value, with patient risk counts at various time points for both groups.*
FDA Label Image

Figure 6b (Figure 6b)

Figure 6b (Figure 6b)
A line graph comparing the percentage of patients with events over 24 months from randomization between FARXIGA and placebo groups. The y-axis shows patients with events (%) and the x-axis shows months. FARXIGA is represented by a solid line, placebo by a dashed line. Patient counts at risk are shown below the x-axis. The graph includes the hazard ratio (HR 0.82, 95% CI: 0.69 to 0.98) and p-value of 0.0294 comparing FARXIGA versus placebo.*
FDA Label Image

Figure 6c (Figure 6c)

Figure 6c (Figure 6c)
A Kaplan-Meier curve comparing the percentage of patients with an event over 24 months between FARXIGA and placebo groups. The vertical axis shows patients with event (%) while the horizontal axis indicates months from randomization. The graph includes a table showing patients at risk over time for each group and statistical data comparing FARXIGA to placebo.*
FDA Label Image

Figure 7 (Figure 7)

Figure 7 (Figure 7)
A forest plot chart showing the hazard ratios (HR) and 95% confidence intervals (CI) for the primary endpoint composite comparing FARXIGA to placebo across multiple patient subgroups by age, sex, race, geographic region, NYHA class, LVEF, NT-proBNP levels, prior hospitalization for heart failure, MRA use, diabetes status, atrial fibrillation/flutter, heart failure etiology, BMI, and baseline eGFR. The plot visualizes HR values with markers and lines, with a scale indicating FARXIGA or placebo benefit.*
FDA Label Image

Dapagliflozin Chemical Structure (Dapagliflozin Struct)

Dapagliflozin Chemical Structure (Dapagliflozin Struct)
Chemical structure of Dapagliflozin, the active ingredient in FARXIGA (dapagliflozin) tablets. The diagram shows the molecular arrangement including functional groups and associated water molecules as part of its hydrated form.*
FDA Label Image

Farxiga 10 mg Bottle Label (Farxiga 10mg 30s)

Farxiga 10 mg Bottle Label (Farxiga 10mg 30s)
FARXIGA 10 mg (dapagliflozin) tablets packaging label showing 30 film-coated oral tablets. The label includes dosage strength, dispensing instructions, and is marked Rx only. The labeler is AstraZeneca Pharmaceuticals LP, with manufacturing details and a 2D barcode visible.*
FDA Label Image

Farxiga 5 mg Bottle Label (Farxiga 5mg 30s)

Farxiga 5 mg Bottle Label (Farxiga 5mg 30s)
Label for FARXIGA (dapagliflozin) tablets, 5 mg strength. The label indicates 30 tablets per bottle with the NDC 0310-6205-30. It includes dispensing instructions, the AstraZeneca Pharmaceuticals LP logo, and spaces for lot number, expiration date, and serial number. The product is identified as a prescription drug.*
FDA Label Image

Figure 1 (Farxiga Fig1)

Figure 1 (Farxiga Fig1)
A scatter plot with dose-response lines showing dapagliflozin dose (mg) on a logarithmic x-axis versus change from baseline (CFB) in 24-hour urinary glucose (g) on the y-axis. The plot displays observed values for healthy subjects and subjects with type 2 diabetes mellitus (T2DM) as distinct symbols, along with fitted dose-response lines for each group.*
FDA Label Image

Figure 8 (Figure 8)

Figure 8 (Figure 8)
A line graph comparing the percentage of patients with an event over time (months from randomization) between FARXIGA and placebo groups. The graph shows FARXIGA with a lower event rate compared to placebo across approximately 32 months. The x-axis represents months from randomization and the y-axis represents the percentage of patients with the event. A patient risk table is also included below.*
FDA Label Image

Farxiga Figure 2 (Image 01)

Farxiga Figure 2 (Image 01)
A line graph depicting adjusted mean percent change from baseline in HbA1c levels over 24 weeks of study in patients treated with FARXIGA 10 mg, FARXIGA 10 mg plus metformin, and metformin alone. The x-axis represents study weeks and the y-axis shows HbA1c percentage change. The graph includes a right-side plot showing values at 24 weeks with last observation carried forward (LOCF), with error bars representing 95% confidence intervals.*
FDA Label Image

Farxiga Figure 3 (Image 02)

Farxiga Figure 3 (Image 02)
A line graph showing adjusted mean change from baseline in HbA1c (%) over 24 weeks comparing FARXIGA 10 mg plus Metformin versus Placebo plus Metformin. The graph includes data points at multiple study weeks and a separate section showing Week 24 values with 95% confidence intervals, illustrating greater HbA1c reduction with FARXIGA 10 mg plus Metformin.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.